Search Results - "Sibilia, J."

Efficacy of anti-TNF alpha in severe and/or refractory Behçet's disease: Multicenter study of 124 patients by Vallet, H, Riviere, S, Sanna, A, Deroux, A, Moulis, G, Addimanda, O, Salvarani, C, Lambert, M, Bielefeld, P, Seve, P, Sibilia, J, Pasquali, Jl, Fraison, Jb, Marie, I, Perard, L, Bouillet, L, Cohen, F, Sene, D, Schoindre, Y, Lidove, O, Le Hoang, P, Hachulla, E, Fain, O, Mariette, X, Papo, T, Wechsler, B, Bodaghi, B, Rigon, M.Resche, Cacoub, P, Saadoun, D

“…Abstract Objective To report the efficacy and safety of anti-TNF agents in patients with severe and/or refractory manifestations of Behçet's disease (BD)…”
Get full text

Schnitzler's syndrome: diagnosis, treatment, and follow‐up by Simon, A., Asli, B., Braun‐Falco, M., Koning, H., Fermand, J.‐P., Grattan, C., Krause, K., Lachmann, H., Lenormand, C., Martinez‐Taboada, V., Maurer, M., Peters, M., Rizzi, R., Rongioletti, F., Ruzicka, T., Schnitzler, L., Schubert, B., Sibilia, J., Lipsker, D.

“…Schnitzler's syndrome is characterized by recurrent urticarial rash and monoclonal gammopathy, associated with clinical and biological signs of inflammation…”
Get full text

Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France by Lequerré, T, Quartier, P, Rosellini, D, Alaoui, F, De Bandt, M, Mejjad, O, Kone-Paut, I, Michel, M, Dernis, E, Khellaf, M, Limal, N, Job-Deslandre, C, Fautrel, B, Le Loët, X, Sibilia, J

“…Anakinra treatment has been reported to be effective in some patients with systemic-onset juvenile idiopathic arthritis (SoJIA) or adult-onset Still disease…”
Get more information

Body mass index and response to tocilizumab in rheumatoid arthritis: a real life study by Gardette, A., Ottaviani, S., Sellam, J., Berenbaum, F., Lioté, F., Meyer, A., Sibilia, J., Fautrel, B., Palazzo, E., Dieudé, P.

“…Several studies have suggested that obesity could have a negative effect on response to anti-tumor necrosis factor α (anti-TNFα) in rheumatoid arthritis (RA)…”
Get full text

Psoriatic arthritis with hyperuricemia: more peripheral, destructive, and challenging to treat by Widawski, L., Fabacher, T., Spielmann, L., Gottenberg, JE, Sibilia, J., Duret, PM, Messer, L., Felten, R.

“…Objective To study the impact of hyperuricemia on clinical presentation, severity, and associated comorbidities of psoriatic arthritis (PsA). Methods…”
Get full text

Tumour necrosis factor α blocking agents in refractory adult Still’s disease: an observational study of 20 cases by Fautrel, B, Sibilia, J, Mariette, X, Combe, B

“…Background: Consensus is lacking on treatment for corticosteroid resistant adult onset Still’s disease (ASD). Objective: To assess anti-TNFα efficacy and…”
Get full text

Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the 'Orencia and Rheumatoid Arthritis' registry by Gottenberg, J E, Ravaud, P, Cantagrel, A, Combe, B, Flipo, R M, Schaeverbeke, T, Houvenagel, E, Gaudin, P, Loeuille, D, Rist, S, Dougados, M, Sibilia, J, Le Loët, X, Marcelli, C, Bardin, T, Pane, I, Baron, G, Mariette, X

“…Very limited data are available regarding the efficacy of abatacept (ABA) in real life. The aims of this study were to determine the efficacy of ABA in…”
Get more information

Tumour necrosis factor   blocking agents in refractory adult Still's disease: an observational study of 20 cases by Fautrel, B

“…Background: Consensus is lacking on treatment for corticosteroid resistant adult onset Still's disease (ASD). Objective: To assess anti-TNFα efficacy and…”
Get full text

Favorable effect of very early disease‐modifying antirheumatic drug treatment on radiographic progression in early inflammatory arthritis: Data from the Étude et Suivi des Polyarthrites IndifféRenciées récentes (Study and Followup of Early Undifferentiated Polyarthritis) by Lukas, C., Combe, B., Ravaud, P., Sibilia, J., Landew, R., van der Heijde, D.

“…Objective While there is consensus that treatment with disease‐modifying antirheumatic drugs (DMARDs) should be started early in patients with inflammatory…”
Get full text

Serum immunoglobulin free light chain assessment in rheumatoid arthritis and primary Sjögren’s syndrome by Gottenberg, J-E, Aucouturier, F, Goetz, J, Sordet, C, Jahn, I, Busson, M, Cayuela, J-M, Sibilia, J, Mariette, X

“…Background: B cell activation may result in an increased secretion of immunoglobulin free light chains (FLCs) in autoimmune diseases. Objective: To analyse…”
Get full text

Fcγ receptor type IIIA polymorphism influences treatment outcomes in patients with rheumatoid arthritis treated with rituximab by Ruyssen-Witrand, A, Rouanet, S, Combe, B, Dougados, M, Le Loët, X, Sibilia, J, Tebib, J, Mariette, X, Constantin, A

“…To assess the association between a single nucleotide polymorphism in the gene of FCGR3A and the response to treatment with rituximab (RTX) in rheumatoid…”
Get more information

Predictive risk factors of serious infections in patients with rheumatoid arthritis treated with abatacept in common practice: results from the Orencia and Rheumatoid Arthritis (ORA) registry by Salmon, J H, Gottenberg, J E, Ravaud, P, Cantagrel, A, Combe, B, Flipo, R M, Schaeverbeke, T, Houvenagel, E, Gaudin, P, Loeuille, D, Rist, S, Dougados, M, Sibilia, J, Le Loët, X, Meyer, O, Solau-Gervais, E, Marcelli, C, Bardin, T, Pane, I, Baron, G, Perrodeau, E, Mariette, X

“…Little data are available regarding the rate and predicting factors of serious infections in patients with rheumatoid arthritis (RA) treated with abatacept…”
Get more information

Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage by Meyer, O, Labarre, C, Dougados, M, Goupille, Ph, Cantagrel, A, Dubois, A, Nicaise-Roland, P, Sibilia, J, Combe, B

“…Objective: To study the value of antibodies to citrullinated proteins/peptides for predicting joint outcomes in patients with recent onset rheumatoid arthritis…”
Get full text

Disease activity score-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis: data from the GUEPARD trial and ESPOIR cohort by Soubrier, M, Lukas, C, Sibilia, J, Fautrel, B, Roux, F, Gossec, L, Patternotte, S, Dougados, M

“…To compare the efficacy of disease activity score in 28 joints (DAS28ESR)-driven therapy with anti-tumour necrosis factor (patients from the GUEPARD trial) and…”
Get more information

NLRP1 influences the systemic sclerosis phenotype: a new clue for the contribution of innate immunity in systemic sclerosis-related fibrosing alveolitis pathogenesis by Dieudé, P, Guedj, M, Wipff, J, Ruiz, B, Riemekasten, G, Airo, P, Melchers, I, Hachulla, E, Cerinic, M Matucci, Diot, E, Hunzelmann, N, Caramaschi, P, Sibilia, J, Tiev, K, Mouthon, L, Riccieri, V, Cracowski, J L, Carpentier, P H, Distler, J, Amoura, Z, Tarner, I, Avouac, J, Meyer, O, Kahan, A, Boileau, C, Allanore, Y

“…Recent evidence has highlighted a potential role of interleukin 1β (IL-1β) in systemic sclerosis (SSc). NLRP1 provides a scaffold for the assembly of the…”
Get more information

Mechanics hands in patients with antisynthetase syndrome: 25 cases by Gusdorf, L., Morruzzi, C., Goetz, J., Lipsker, D., Sibilia, J., Cribier, B.

“…Antisynthetase antibodies (ASA) are directed against aminoacyl-tRNA-synthetases, ubiquitous enzymes of which eight types have hitherto been described. They are…”
Get full text

Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases by Gottenberg, J-E, Guillevin, L, Lambotte, O, Combe, B, Allanore, Y, Cantagrel, A, Larroche, C, Soubrier, M, Bouillet, L, Dougados, M, Fain, O, Farge, D, Kyndt, X, Lortholary, O, Masson, C, Moura, B, Remy, P, Thomas, T, Wendling, D, Anaya, J-M, Sibilia, J, Mariette, X

“…Objective: To assess the tolerance and efficacy of rituximab in patients with various autoimmune diseases seen in daily rheumatological practice. Methods: 866…”
Get full text

Efficacy and tolerance of infliximab in refractory Takayasu arteritis: French multicentre study by MEKINIAN, Arsène, NEEL, Antoine, MARIE, Isabelle, GUILLEVIN, Loïc, HAMIDOU, Mohamed, FAIN, Olivier, SIBILIA, Jean, COHEN, Pascal, CONNAULT, Jerome, LAMBERT, Marc, FEDERICI, Laure, BERTHIER, Sabine, FIESSINGER, Jean-Noel, GODEAU, Bertrand

“…To analyse the efficacy and tolerance of infliximab in refractory Takayasu arteritis (TA). French multicentre retrospective study that included patients with…”
Get full text

European League Against Rheumatism Sjögren's Syndrome Disease Activity Index and European League Against Rheumatism Sjögren's Syndrome Patient‐Reported Index: A Complete Picture of Primary Sjögren's Syndrome Patients by Seror, R., Gottenberg, J. E., Devauchelle‐Pensec, V., Dubost, J. J., Le Guern, V., Hayem, G., Fauchais, A.‐L., Goeb, V., Hachulla, E., Hatron, P. Y., Larroche, C., Morel, J., Pedriger, A., Puechal, X., Rist, S., Saraux, A., Sene, D., Sibilia, J., Vittecoq, O., Zarnitsky, C., Labetoulle, M., Ravaud, P., Mariette, X.

“…Objective The European League Against Rheumatism (EULAR) Sjögren's Syndrome (SS) Disease Activity Index (ESSDAI) and the EULAR SS Patient‐Reported Index…”
Get full text

Efficacy of abatacept in systemic lupus erythematosus: a retrospective analysis of 11 patients with refractory disease by Danion, F, Rosine, N, Belkhir, R, Gottenberg, J E, Hachulla, E, Chatelus, E, Pugnet, G, Pers, Y M, Mariette, X, Sibilia, J, Seror, R

“…Objective The objective of this study was to assess the safety and efficacy of abatacept in patients with SLE refractory to conventional treatment in routine…”
Get full text